Insights into Doublet Therapy and Clinical Trial Takeaways for Metastatic Prostate Cancer Treatment
Fred Saad, CQ, MD, FRCS, FCAHS, discusses how recent clinical trials, including ARASENS and ARANOTE, have expanded treatment options for metastatic prostate cancer, highlighting the efficacy and safety of combining darolutamide with androgen deprivation therapy and/or chemotherapy while considering patient-specific factors to guide individualized treatment decisions.
Pedro Barata, MD, MSc FACP, discusses how recent clinical trials have advanced the treatment of metastatic prostate cancer, focusing on the efficacy of combination therapies involving radium-223, AR-targeted agents, and PARP inhibitors, while addressing safety concerns and considering optimal treatment strategies for different patient populations.
EP. 1: Therapeutic Combination Therapies for Metastatic Prostate Cancer
September 30th 2024Fred Saad, CQ, MD, FRCS, FCAHS, discusses how combining therapies like androgen receptor–targeted agents, androgen deprivation therapy, and docetaxel can potentially improve outcomes for metastatic prostate cancer patients, with treatment selection influenced by factors such as disease volume and risk level.
EP. 2: Patient-Centered Approach to Use of Chemotherapy in Metastatic Prostate Cancer
September 30th 2024The panelist discusses how incorporating chemotherapy into combination treatments for metastatic prostate cancer presents challenges such as increased resource requirements, the need for interdisciplinary collaboration, and potential inconveniences for patients, including more frequent clinic visits and laboratory monitoring.
